Exogenously added TNF or cell-free supernatant from proteasomal inhibitor-treated immune or multiple myeloma cells combined with TNF, further compromises the cellular integrity of HPMECs when compared to drug alone conditions. This evidence concerns the gene TNF and AL amyloidosis.